Mode
Text Size
Log in / Sign up

MASLD is associated with higher CKD prevalence and accelerated renal impairment progressionLiver disease and fatty liver are linked to kidney damage

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note the association between MASLD and increased CKD prevalence and accelerated progression of renal impairment.

This meta-analysis evaluates the link between metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic kidney disease (CKD). The analysis focuses on adults diagnosed with MASLD via imaging or validated non-invasive indices, comparing them to individuals without the condition. The study identifies a positive association between MASLD and incident CKD, alongside a higher prevalence of CKD in patients with MASLD.

Furthermore, the authors synthesize findings indicating that liver fibrosis significantly increases the risk of renal impairment and accelerates its progression. These results suggest that liver fibrosis may serve as a key determinant in the progression of renal damage within this patient population.

Limitations include potential selection bias from a single reviewer during study selection and high heterogeneity in quantitative analysis due to methodological and clinical differences. Because of this substantial heterogeneity, the precision of the meta-analysis is limited. The findings highlight the importance of early identification of renal damage in MASLD patients and suggest integrating non-invasive fibrosis assessment tools into clinical practice.

Living with a fatty liver can do more than just affect your liver. New research shows that people with metabolic dysfunction-associated steatotic liver disease (MASLD) are at a much higher risk for serious kidney problems. The study found that those with this condition had a higher prevalence of chronic kidney disease compared to people without it.

The data suggests that the severity of liver damage plays a major role in how your kidneys are affected. Specifically, liver fibrosis—which is the scarring of liver tissue—was linked to a faster progression of kidney impairment. This means that as the liver becomes more scarred, the risk of kidney issues increases significantly.

While these findings highlight a clear link between the two conditions, it is important to note that the study shows an association rather than a direct cause. Because the data came from many different types of studies with varying methods, some results should be viewed with caution. However, the findings suggest that doctors should look for early signs of kidney damage in patients with liver issues.

What this means for you:
People with fatty liver disease are at higher risk for kidney problems, especially if they have significant liver scarring.

Common questions

How does liver disease affect the kidneys?

People with metabolic dysfunction-associated steatotic liver disease (MASLD) show a higher prevalence of chronic kidney disease compared to those without the condition. Specifically, when liver fibrosis—the scarring of liver tissue—is present, it significantly increases the risk of renal impairment and causes kidney problems to progress faster.

Is there a specific link between liver scarring and kidney health?

Yes, the study found that liver fibrosis is a key factor. When liver tissue becomes scarred, it is linked to an increased risk of renal impairment. This suggests that the extent of damage to the liver can directly influence how quickly kidney function declines in patients with MASLD.

Is this finding certain for everyone with fatty liver?

The study shows a clear association between these conditions, but it is not a guaranteed cause for every individual. Because the data came from many different studies with varying methods, there is some uncertainty in the exact measurements. You should talk to your doctor about how these findings apply to your specific health needs.

Study Details

Study typeMeta analysis
EvidenceLevel 1
Follow-up12.0 mo
PublishedJan 2026
View Original Abstract ↓
Metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic kidney disease (CKD) are highly prevalent conditions that share pathophysiological mechanisms. The possible bidirectional association between these diseases has gained increasing relevance, particularly due to the prognostic role of liver fibrosis in renal outcomes. This systematic review aims to update the current knowledge on this topic. A systematic review was conducted following the PRISMA 2020 guidelines. The literature search was performed in PubMed, Scopus, and Web of Science, covering the period from August 2020 to February 2025, without language restrictions. Prospective studies with at least 12 months of follow-up were included, enrolling adults with MASLD diagnosed by imaging techniques or validated non-invasive indices. Renal outcomes of interest were reduced glomerular filtration rate (GFR <60mL/min/1.73 m) or albuminuria (≥30mg/g). Study selection and analysis were performed by a single reviewer, which represents a potential limitation due to the increased risk of selection bias. Data were systematically extracted and synthesized, focusing on the incidence, prevalence, and progression of CKD in patients with MASLD. A meta-analysis was subsequently performed using the inverse-variance method under a fixed-effects model, and results were reported as odds ratios (ORs) with 95% confidence intervals (CIs). Statistical heterogeneity was assessed using Cochran's Q test (X) and quantified with the I statistic. Eighteen studies met the inclusion criteria. Most reported a positive association between MASLD and incident CKD. Liver fibrosis was consistently identified as a key determinant, significantly increasing the risk of renal impairment and accelerating its progression. The prevalence of CKD was higher in patients with MASLD compared to individuals without the condition. However, in the quantitative analysis heterogeneity was generally high, reflecting methodological and clinical differences among the included studies. MASLD is associated with an increased risk and faster progression of CKD, particularly in the presence of advanced fibrosis. These findings highlight the need for early identification of renal damage in MASLD patients and support the integration of non-invasive fibrosis assessment tools into clinical practice. However, the results should be interpreted with caution due to the substantial heterogeneity observed.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.